IP Library › Patent Application 19206359
Patent Application
App. No. 19/206,359

MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/206,359
Filed
May 13, 2025
Art Unit
OPAP
USPC
514/267
Abstract

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Claims (11)

1 - 89 . (canceled)

90 . Crystalline Form E of Compound 1:

91 . Crystalline Form E according to claim 90 in substantially pure form.

92 . Crystalline Form E according to claim 90 , characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 7.0±0.2, 11.2±0.2, 12.8±0.2, 13.2±0.2, 14.1±0.2, 15.1±0.2, 16.1±0.2, 17.8±0.2, and 18.9±0.2.

93 . Crystalline Form E according to claim 90 , characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 11.2±0.2, 12.8±0.2, 13.2±0.2, 15.1±0.2, 16.1±0.2, and 17.8±0.2.

94 . Crystalline Form E according to claim 90 , characterized by an X-ray powder diffractogram having a signal at three two-theta values of 12.8±0.2, 16.1±0.2, and 17.8±0.2.

95 . Crystalline Form E according to claim 90 , characterized by an X-ray powder diffractogram having a signal at six two-theta values of 11.2±0.2, 12.8±0.2, 13.2±0.2, 15.1±0.2, 16.1±0.2, and 17.8±0.2.

96 . Crystalline Form E of claim 90 , characterized by an X-ray powder diffractogram substantially similar to that in FIG. 14 .

97 - 125 . (canceled)

126 . Crystalline Form E according to claim 90 , characterized by an X-ray powder diffractogram having a signal at four two-theta values of 11.2±0.2, 12.8±0.2, 13.2±0.2, 15.1±0.2, 16.1±0.2, and 17.8±0.2.

127 . Crystalline Form E according to claim 90 , characterized by an X-ray powder diffractogram having a signal at five two-theta values of 11.2±0.2, 12.8±0.2, 13.2±0.2, 15.1±0.2, 16.1±0.2, and 17.8±0.2.